Ipilimumab bulk supplier for pharma manufacturers

Ipilimumab 5 mg/1 mL (vial) Suppliers & Bulk Manufacturers

Available Forms: Injection

Available Strengths: 5 mg/1 mL (vial)

Reference Brands: Yervoy® (EU & US)

pilimumab (brand name Yervoy®) is a monoclonal antibody used in oncology to treat cancers like melanoma, renal cell carcinoma (RCC), and non-small cell lung cancer (NSCLC). It works by blocking the CTLA-4 receptor on T-cells, which enhances the immune system’s ability to attack cancer cells. It is available in intravenous (IV) form with a strength of 5 mg/1 mL.

Get Enquiry / Request Bulk Quote

Usually answered within 48 hours | GMP documents shared before you commit

Manufacture or export Ipilimumab? List it or send an offer →

Product Description: Ipilimumab (brand name Yervoy®) is a monoclonal antibody used in oncology as an immune checkpoint inhibitor. By blocking the CTLA-4 receptor on T-cells, Ipilimumab enhances the body’s immune response, allowing T-cells to more effectively recognize and attack cancer cells. It is primarily used in the treatment of melanoma, renal cell carcinoma (RCC), and non-small cell lung cancer (NSCLC), among other cancers. Ipilimumab is often combined with nivolumab (Opdivo®) for improved efficacy, especially in metastatic melanoma and other advanced cancers. It is administered as an intravenous (IV) infusion, available in a 5 mg/1 mL vial.

Ipilimumab — third party manufacturing & bulk supply

Ipilimumab 5 mg/1 mL (vial) is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Ipilimumab is supplied as Injection — an injectable dosage form, so the indicative MOQ is 50,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Ipilimumab listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Ipilimumab →

Usually answered within 48 hours, with matched manufacturers, indicative prices and document status.

Back to Listing

Frequently Asked Questions

Ipilimumab is listed as Injection in 5 mg/1 mL (vial). Further strengths and pack presentations are confirmed with the manufacturer at RFQ stage.

Ipilimumab is referenced against Yervoy® (EU & US). Reference brands are shown for identification only and remain the property of their respective trademark owners.